Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661578 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT05661578 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 64 participants.
The verdict
NCT05661578, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected solid tumors whose disease is locally advanced, recurrent, or metastatic and for whom an investigational agent in combination with an anti-PD-L1 antibody is considered an acceptable treatment option.
Interventions
- DRUG Tiragolumab and Atezolizumab IV FDC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-05-04 |
| Est. Completion | 2025-12-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05661578
The ClinicalTrials.gov registry entry for NCT05661578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tiragolumab and Atezolizumab IV FDC is the first listed.
NCT05661578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05661578 about?
NCT05661578 is a clinical study titled "A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors". The purpose of this study is to assess the safety, pharmacokinetics, and immunogenicity of tiragolumab and atezolizumab intravenous fixed-dose combination (IV FDC) in participants with histologically confirmed PD-L1-selected solid tumors whose disease is locally advanced, recurrent, or metastatic an...
What is the current status of trial NCT05661578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-05-04. Estimated completion is 2025-12-26.
What interventions are being tested in trial NCT05661578?
The interventions under investigation include: Tiragolumab and Atezolizumab IV FDC (DRUG).
Who is sponsoring clinical trial NCT05661578?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.